Early TNF Inhibitor Use Improves Outcomes in Nonsystemic JIA

Early TNF Inhibitor Use Improves Outcomes in Nonsystemic JIA

Early initiation of TNF inhibitors among children with non-sJIA led to significant and sustained improvements in disease activity.

Research presented at the American College of Rheumatology (ACR) Convergence 2025 found that early initiation of tumor necrosis factor (TNF) inhibitor therapy among children diagnosed with nonsystemic juvenile idiopathic arthritis (non-sJIA) at 2 years or less leads to significant and sustained improvements in disease activity.

Using data from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry from 2015 to 2023, researchers described the demographic and disease characteristics of children diagnosed with non-sJIA when aged from 0 to 23 months.

Outcomes were comparable to patients who received treatment later in life and those not exposed to TNF inhibitors.

Author's summary: Early TNF inhibitor use improves non-sJIA outcomes.

more

Rheumatology Advisor Rheumatology Advisor — 2025-10-27

More News